|Bid||25.55 x 1300|
|Ask||27.50 x 1800|
|Day's Range||24.64 - 29.49|
|52 Week Range||17.20 - 70.29|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.88|
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) investors concerning the Company’s possible violations of the federal securities laws.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.